| Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma (NCT05089370) | University of Colorado, Denver | 2022-06-20 |
| Diagnostic Precision of the AI Tool Dermalyzer to Identify Malignant Melanomas in Subjects Seeking Primary Care for Melanoma-suspected Cutaneous Lesions (NCT05172232) | Linkoeping University | 2022-05-02 |
| Fast Track Diagnosis of Skin Cancer by Advanced Imaging Technologies and Tumour Tapestripping (NCT05389085) | University Hospital Bispebjerg and Frederiksberg | 2022-05-01 |
| A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors (NCT05293496) | MacroGenics | 2022-04-19 |
| Shared Decision Making in Melanoma Patients Receiving Adjuvant Therapy (NCT06294379) | Odense University Hospital | 2022-03-01 |
| The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors (NCT05037825) | VastBiome | 2021-11-22 |
| Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib) (NCT04547946) | Novartis Pharmaceuticals | 2021-10-15 |
| ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma (NCT04904185) | Inge Marie Svane | 2021-09-17 |
| RAPA-201 Therapy of Solid Tumors (NCT05144698) | Rapa Therapeutics LLC | 2021-08-01 |
| A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201) (NCT04913220) | Sanofi | 2021-07-15 |
| L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma (NCT04924413) | Quanli Gao | 2021-07-01 |
| First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies (NCT04763083) | NovalGen Ltd. | 2021-05-14 |
| Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery (NCT04879654) | Eye & ENT Hospital of Fudan University | 2021-05-01 |
| A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma (NCT04884997) | First Affiliated Hospital of Zhejiang University | 2021-03-07 |
| ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases (NCT03448666) | European Institute of Oncology | 2021-03-01 |
| A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement (NCT04543188) | Pfizer | 2021-01-08 |
| Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas (NCT04285749) | Case Comprehensive Cancer Center | 2020-11-06 |
| Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract (NCT04593485) | Fudan University | 2020-10-28 |
| A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors (NCT04452214) | Cantargia AB | 2020-09-24 |
| Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract (NCT05478876) | CNAO National Center of Oncological Hadrontherapy | 2020-09-03 |
| Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma (NCT04223648) | Yale University | 2020-08-15 |
| Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study (NCT04889118) | Merck Sharp & Dohme LLC | 2020-07-14 |
| A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer (NCT06636435) | Chiome Bioscience Inc. | 2020-06-01 |
| UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma (NCT04382664) | Ultimovacs ASA | 2020-05-27 |
| Pre Transplantation Melanoma (NCT04217382) | Hospices Civils de Lyon | 2020-02-27 |
| A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma (NCT04123470) | Lokon Pharma AB | 2020-01-28 |
| A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma (NCT04126876) | A.J.M. van den Eertwegh | 2020-01-22 |
| Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma (NCT04293289) | Cancer Intelligence Care Systems, Inc. | 2019-11-19 |
| SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) (NCT04079166) | Scancell Ltd | 2019-08-19 |
| This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO) (NCT03780608) | Samsung Medical Center | 2019-07-30 |
| Neurofilament Light Protein in Peripheral Blood Used as a Biomarker for Neurotoxicity After Isolated Limb Perfusion. (NCT04460053) | Vastra Gotaland Region | 2019-04-12 |
| Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) (NCT03820986) | Merck Sharp & Dohme LLC | 2019-03-12 |
| Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors (NCT03689192) | Herlev Hospital | 2018-12-17 |
| Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy (NCT03649529) | Timmune Biotech Inc. | 2018-09-27 |
| High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs (NCT03653819) | Herlev and Gentofte Hospital | 2018-09-06 |
| Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (NCT03551626) | Novartis Pharmaceuticals | 2018-08-29 |
| Phase Ib of L-NMMA and Pembrolizumab (NCT03236935) | The Methodist Hospital Research Institute | 2018-08-27 |
| Test of Interventions to Prevent Skin Cancer Among Danes on Vacation in High UV Index Sunny Destinations (NCT03607578) | Brian Køster | 2018-08-01 |
| UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma (NCT03538314) | Ultimovacs ASA | 2018-07-09 |
| E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) (NCT03332589) | Spirita Oncology, LLC | 2018-07-02 |
| Melanoma Metastasized to the Brain and Steroids (NCT03563729) | Inge Marie Svane | 2018-06-06 |
| Real World Study of Four PD-1 Agents in China (NCT03966456) | The Affiliated Hospital of Qingdao University | 2018-06-01 |
| Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma (NCT02902042) | Prof. Dr. med. Dirk Schadendorf | 2018-04-24 |
| PET Imaging of the Immune System Using Analog Probes (NCT03409419) | Jonsson Comprehensive Cancer Center | 2018-04-10 |
| Suction Drain in Axillary Lymph Node Dissection for Malignant Melanoma (NCT04648163) | Medical University of Graz | 2017-12-01 |
| Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma (NCT03383237) | Henan Cancer Hospital | 2017-11-29 |
| 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy (NCT03278665) | 4SC AG | 2017-09-25 |
| Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study (NCT03545334) | Insel Gruppe AG, University Hospital Bern | 2017-09-01 |
| Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients (NCT03197636) | Aarhus University Hospital | 2017-08-11 |
| The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial (NCT03158935) | University Health Network, Toronto | 2017-07-07 |
| A Randomized Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of High Risk Melanoma (NCT03116412) | Uppsala University | 2017-06-08 |
| Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma (NCT03084640) | Regeneron Pharmaceuticals | 2017-05-04 |
| Study of 1cm Versus 2cm Margins for the Surgical Treatment of cT2N0M0 Melanoma (NCT03034395) | University of Kansas Medical Center | 2017-01-30 |
| Melanoma Image Analysis Algorithm (MIAA) Validation Study (NCT02612168) | Skin Analytics Limited | 2017-01-11 |
| IMCgp100-401 Rollover Study (NCT02889861) | Immunocore Ltd | 2017-01-11 |
| A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients (NCT02661100) | Case Comprehensive Cancer Center | 2017-01-01 |
| Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET) (NCT03060356) | University of Pennsylvania | 2016-12-21 |
| Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced Melanoma (NCT02938728) | Assistance Publique - Hôpitaux de Paris | 2016-11-01 |
| Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma (NCT02902029) | University Hospital, Essen | 2016-11-01 |
| A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer (NCT02897765) | BioNTech US Inc. | 2016-10-01 |
| Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab (NCT02935790) | Celgene | 2016-09-30 |
| Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors (NCT02709889) | AbbVie | 2016-09-23 |
| Neoadjuvant L19IL2/L19TNF- Pivotal Study (NCT02938299) | Philogen S.p.A. | 2016-07-01 |
| Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (NCT02644369) | University Health Network, Toronto | 2016-03-21 |
| ImmuniCell® in Patients With Advanced Cancers (NCT02459067) | TC Biopharm | 2015-12-01 |
| Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis (NCT02537600) | Center Eugene Marquis | 2015-12-01 |
| Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma (NCT02535078) | Immunocore Ltd | 2015-11-01 |
| Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma (NCT02410863) | Prof. Dr. med. Dirk Schadendorf | 2015-11-01 |
| PLX3397 KIT in Acral aNd mucOsal Melanoma (NCT02071940) | The Christie NHS Foundation Trust | 2015-10-01 |
| Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma (NCT02574533) | Gradalis, Inc. | 2015-10-01 |
| Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma (NCT02650492) | Clinical Laserthermia Systems AB | 2015-10-01 |
| Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED (NCT02523313) | Prof. Dr. med. Dirk Schadendorf | 2015-09-02 |
| Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients. (NCT02718391) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2015-08-01 |
| GI Complications in Cancer Immunotherapy Patients (NCT02784366) | Massachusetts General Hospital | 2015-08-01 |
| Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER) (NCT02452294) | University Hospital Tuebingen | 2015-07-01 |
| Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer (NCT02331134) | University of Colorado, Denver | 2015-05-13 |
| Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma (NCT02275416) | Ultimovacs ASA | 2015-02-02 |
| Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC (NCT02303951) | University Hospital Tuebingen | 2015-01-22 |
| Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma (NCT02673970) | Universitair Ziekenhuis Brussel | 2014-10-01 |
| Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients (NCT02296996) | Universitair Ziekenhuis Brussel | 2014-10-01 |
| Comparison of PET/CT and Ultrasound in Staging of Malignant Melanoma (NCT04253574) | University of Basel | 2014-09-01 |
| A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma (NCT02272855) | Takara Bio Inc. | 2014-04-30 |
| Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma (NCT02316795) | Washington University School of Medicine | 2014-02-01 |
| A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. (NCT02068196) | Oslo University Hospital | 2014-01-01 |
| Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors (NCT01962103) | Celgene | 2013-12-04 |
| A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma (NCT02050321) | University of Arizona | 2013-12-01 |
| An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma (NCT01898585) | Hoffmann-La Roche | 2013-10-17 |
| A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma (NCT01910181) | Hoffmann-La Roche | 2013-08-17 |
| Modified Vaccine for High Risk or Low Residual Melanoma Patients (NCT01898039) | Hadassah Medical Organization | 2013-05-01 |
| An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS) (NCT01990248) | Hoffmann-La Roche | 2013-03-23 |
| Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary (NCT02828202) | Assistance Publique - Hôpitaux de Paris | 2013-02-01 |
| A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma (NCT01689519) | Hoffmann-La Roche | 2013-01-08 |
| A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370) (NCT01636960) | Merck Sharp & Dohme LLC | 2012-12-25 |
| Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples (NCT01744860) | Hoffmann-La Roche | 2012-12-01 |
| Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma (NCT01696045) | Bristol-Myers Squibb | 2012-11-12 |
| A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma (NCT01656642) | Genentech, Inc. | 2012-08-13 |
| Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients (NCT01543464) | Inge Marie Svane | 2012-05-01 |
| Anesthesia and Cancer Recurrence im Malignant Melanoma (NCT01588847) | University Hospital Muenster | 2012-03-01 |
| A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma (NCT01522664) | Genentech, Inc. | 2012-03-01 |
| A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001 (NCT01559818) | Immodulon Therapeutics Ltd | 2012-02-01 |